Home/Pipeline/JUV-161

JUV-161

Myotonic Dystrophy Type 1

Phase 1Active

Key Facts

Indication

Myotonic Dystrophy Type 1

Phase

Phase 1

Status

Active

Company

Juvena Therapeutics

About Juvena Therapeutics

Juvena Therapeutics is a private, preclinical-stage biotech founded in 2018 and headquartered in Redwood City, California. The company has developed a proprietary AI-powered platform to systematically map the therapeutic potential of secreted proteins and engineer them into biologics aimed at restoring tissue homeostasis. Its lead program, JUV-161 for Myotonic Dystrophy Type 1, has received FDA Orphan Drug Designation and entered first-in-human trials in 2025, supported by a significant research collaboration with Eli Lilly. Juvena is targeting a broad range of degenerative conditions associated with unhealthy aging.

View full company profile

Therapeutic Areas

Myopathies Metabolic Diseases

Other Myotonic Dystrophy Type 1 Drugs

Drug	Company	Phase	Status
DM1 Therapy	Kinea Bio	Research	Active
PPR Editor for DM1	EditForce	Preclinical	Active
ENTR-701	Entrada Therapeutics	Phase 1	Active